Clinical Trial Update: Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating MAC-321 in platinum-refractory non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MAC-321

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 2 | Status: COMPLETED